scholarly journals Age of 40 Years or Younger Is an Independent Risk Factor for Locoregional Failure in Early Breast Cancer: A Single-Institutional Analysis in Saudi Arabia

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Volker Rudat ◽  
Hamdan El-Sweilmeen ◽  
Elias Fadel ◽  
Iris Brune-Erber ◽  
Alaa Ahmad Nour ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Univariate Analysis ◽  
Tumor Type ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Locoregional Failure ◽  
T Stage ◽  
The Impact

Background. This study was undertaken to evaluate the impact of prognostic factors on the locoregional failure-free survival of early breast cancer patients.Methods. In this single-institutional study, 213 breast cancer patients were retrospectively analysed. Fifty-five of 213 patients were ≤40 years of age at diagnosis. The impact of patient- or treatment-related factors on the locoregional failure-free survival was assessed using the Kaplan-Meier method. The simultaneous impact of factors on the locoregional failure-free survival was assessed using the Cox proportional hazards regression analysis.Results. The median follow-up time of the censored patients was 22 months (mean 28 months, range 3–92 months). On univariate analysis, statistically significant factors for the locoregional failure-free survival were the age (≤40 versus >40 years), T stage (Tis, T0–2 versus T3-4), molecular tumor type (luminal A versus luminal B, Her2neu overexpression, or triple negative), and lymphovascular status (LV0 versus LV1). On multivariate analysis, age and T stage remained statistically significant.Conclusions. Being 40 years or younger has a statistically significant independent adverse impact on the locoregional failure-free survival of patients with early breast cancer.

scholarly journals SULT1A1,CYP2C19and disease-free survival in early breast cancer patients receiving tamoxifen

2011 ◽  
Vol 12 (11) ◽  
pp. 1535-1543 ◽  
Author(s):  
Ann M Moyer ◽  
Vera J Suman ◽  
Richard M Weinshilboum ◽  
Rajeswari Avula ◽  
John L Black ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free

scholarly journals Prediction of Non-Sentinel Lymph Node Metastasis by Molecular Assay in Whole Sentinel Lymph Node Analysis in Breast Cancer Patients

2017 ◽  
Vol 35 (2) ◽  
pp. 149
Author(s):  
Suphawat Laohawiriyakamol ◽  
Puttisak Puttawibul ◽  
Somrit Mahattanobon ◽  
Supparerk Laohawiriyakamol
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Predictive Factor ◽  
Univariate Analysis ◽  
Breast Cancer Patients ◽  
Operating Characteristics ◽  
Osna Assay

Objective: To determine whether the total tumor load (TTL) as indicated through the one-step nucleic acid amplification(OSNA) assay can be a predictive factor of non-sentinel lymph node (SLN) metastasis in early breast cancer patients.Material and Method: The records of 102 patients with cT1-3N0 breast cancer who had an intraoperative SLN evaluationperformed through an OSNA assay at Songklanagarind Hospital between 1 January 2015 and 30 May 2016 were examined.Results: Univariate analysis found TTL, tumor size, presence of lymphovascular invasion, and macrometastasis weresignificant predictive factors of non-SLN metastasis. In the multivariate analysis, TTL was the only predictive factor withstatistical significance (OR 1.1, 95% CI=1.0, 1.2). The area under the receiver operating characteristics (ROC) curve ofTTL was 0.9 (95% CI=0.8, 0.9).Conclusion: TTL is a significant predictive factor of non-SLN metastasis in early breast cancer patients.

Predicting possibility of positive non-sentinel nodes in sentinel node–positive breast cancer patients: A Singapore series.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 51-51
Author(s):  
W. S. Yong ◽  
M. H. Chang ◽  
W. J. J. Chen
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Univariate Analysis ◽  
Good Prediction ◽  
Breast Cancer Patients ◽  
Prediction Ability ◽  
Sentinel Nodes ◽  
Axillary Clearance

51 Background: Sentinel lymph node (SLN) biopsy is an accepted method for determining the axillary status in early breast cancer patients. If positive, a standard axillary clearance is performed. However, recent studies have shown that many of these patients may not have additional positive non sentinel nodes, and the removal of these additional nodes may not be necessary or confer any benefit. We set out to identify factors that determine non sentinel node positivity and whether this could be predicted from our series of early breast cancer patients. Methods: We retrospectively reviewed 337 of our early breast cancer patients from 2005 to 2008 who had atleast one positive sentinel node and had undergone a full axillary clearance. Tumour factors and sentinel node variables were collected and compared between those patients with additional positive non sentinel nodes and those with no positive nodes in the axillary clearance. Results: Five factors were found on univariate analysis to be associated with non sentinel node positivity. They are ratio of positive SLN to total number of SLN, number of positive SLNs, size of metastasis in the SLN, tumour size and lymphovascular invasion. The first 3 factors were used to model a logistic-regression model which has good prediction ability to predict positivity of non SLNs (value under ROC curve 0.726 [95% CI 0.666-0.786]). Conclusions: Tumor factors and SLN variables are able to help us predict the possibilty of additional positive non SLN once at least a SLN is positive. This can help the surgeon and patient in the decision making process on the need for a full axillary clearance.

scholarly journals Circulating Tumor Cells in Early Breast Cancer

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Laura Thery ◽  
Alessandra Meddis ◽  
Luc Cabel ◽  
Charlotte Proudhon ◽  
Aurelien Latouche ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Breast Cancer ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Level Of Evidence ◽  
Free Survival ◽  
Meta Analyses

AbstractCirculating tumor cells (CTCs) are particularly rare in non-metastatic breast cancer, and the clinical validity of CTC detection in that clinical setting was initially not well recognized. A cytological CTC detection device (CellSearch) fulfilling the CLIA requirements for analytical validity was subsequently developed and, in 2008, we reported the first study (REMAGUS02) showing that distant metastasis-free survival was shorter in early breast cancer patients with one or more CTCs. In the past 10 years, other clinical studies and meta-analyses have established CTC detection as a level-of-evidence 1 prognostic biomarker for local relapses, distant relapses, and overall survival. This review summarizes available data on CTC detection and the promises of this proliferation- and subtype-independent metastasis-associated biomarker in early breast cancer patients.

scholarly journals Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

2021 ◽  
Author(s):  
Paulina Karin Grillo ◽  
Balázs Győrffy ◽  
Martin Götte
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Heparan Sulfate ◽  
Cancer Patients ◽  
Heparan Sulfate Proteoglycans ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
The Impact

Abstract Purpose Dysregulated expression of proteoglycans influences the outcome and progression of numerous cancers. Several studies have investigated the role of individual glypicans in cancer, however, the impact of the whole glypican family of heparan sulfate proteoglycans on prognosis of a large patient cohort of breast cancer patients has not yet been investigated. In the present study, our aim was to investigate the prognostic power of the glypicans in breast cancer patients. Methods We used a public database including both gene expression data and survival information for 3951 breast cancer patients to determine the prognostic value of glypicans on relapse-free survival using Cox regression analysis. Moreover, we performed quantitative Real-Time PCR to determine glypican gene expression levels in seven representative breast cancer cell lines. Results We found that high GPC3 levels were associated with a better prognosis in overall breast cancer patients. When stratified by hormone receptor status, we found that in worse prognosis subtypes low GPC1 levels correlate with a longer relapse-free survival, and in more favorable subtypes low GPC6 was associated with longer survival. Conclusion Our study concludes that glypicans could act as subtype-specific biomarkers for the prognosis of breast cancer patients and sparks hope for future research on glypicans possibly eventually providing targets for the treatment of the disease.

Sign in / Sign up

Export Citation Format

Share Document